Adam Mohamed, Gameraddin Moawia, Alelyani Magbool, Alshahrani Mohammad Y, Gareeballah Awadia, Ahmad Irshad, Azzawi Abdulrahman, Komit Basem, Musa Alamin
Department of Radiological Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Department of Diagnostic Radiologic Technology, Faculty of Applied Medical Sciences, Taibah University, Al-Madinah, Saudi Arabia.
Patient Prefer Adherence. 2021 Sep 7;15:1963-1970. doi: 10.2147/PPA.S330689. eCollection 2021.
The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown promising safety and acceptability. However, COVID-19 vaccine side effects play an essential role in public vaccine confidence. We aimed to study the side effects of these COVID-19 vaccines.
A randomized, cross-sectional descriptive study was conducted between March and May of 2021. In total, 330 participants among the King Khalid University community in the Aseer region of the Kingdom of Saudi Arabia reported their side effects following the COVID-19 vaccine. A questionnaire was designed and validated to collect the participants' demographic data and COVID-19-related symptoms after COVID-19 vaccine injection.
Symptoms associated with COVID-19 were reported by 226 participants (68.5%). The most common side effects reported by the participants were fever (n = 136, 41.2%), fatigue (n = 119, 36.1%), headache (n = 86, 24.2%), malaise (n = 121, 36.7%), myalgia (n = 121, 36.7%), and muscle and joint pain (n = 76, 23%). Of the participants, 5.1% became infected with COVID-19 after vaccination. Symptoms were significantly more common in males than in females (p = 0.006).
The incidence of COVID-19 vaccination side effects in the Aseer region, Kingdom of Saudi Arabia, was consistent with the manufacturers' data. The most common post-vaccination symptoms reported by the participants were fever, myalgia, malaise, fatigue, muscle and joint pain, and headache. The results of this study showed significant variation in adverse events between Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines. Healthcare providers and recipients of vaccines can be more confident about the safety of Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines.
辉瑞-生物科技公司(BNT162b2)和牛津-阿斯利康公司(ChAdOx1 nCoV-19)的新冠疫苗已显示出良好的安全性和可接受性。然而,新冠疫苗的副作用在公众对疫苗的信心方面起着至关重要的作用。我们旨在研究这些新冠疫苗的副作用。
于2021年3月至5月进行了一项随机横断面描述性研究。沙特阿拉伯王国阿西尔地区阿卜杜勒-阿齐兹国王大学社区的330名参与者报告了他们接种新冠疫苗后的副作用。设计并验证了一份问卷,以收集参与者的人口统计学数据以及接种新冠疫苗后的新冠相关症状。
226名参与者(68.5%)报告了与新冠相关的症状。参与者报告的最常见副作用为发热(n = 136,41.2%)、疲劳(n = 119,36.1%)、头痛(n = 86,24.2%)、不适(n = 121,36.7%)、肌痛(n = 121,36.7%)以及肌肉和关节疼痛(n = 76,23%)。在参与者中,5.1%在接种疫苗后感染了新冠。症状在男性中比在女性中更为常见(p = 0.006)。
沙特阿拉伯王国阿西尔地区新冠疫苗接种副作用的发生率与制造商的数据一致。参与者报告的最常见接种后症状为发热、肌痛、不适、疲劳、肌肉和关节疼痛以及头痛。本研究结果显示,辉瑞-生物科技公司和牛津-阿斯利康公司的新冠疫苗在不良事件方面存在显著差异。医疗保健提供者和疫苗接种者可以对辉瑞-生物科技公司和牛津-阿斯利康公司的新冠疫苗的安全性更有信心。